5. The licence holder must ensure that any blood or blood component imported into the United Kingdom and used by the manufacturer's licence holder as a starting material or raw material in the manufacture of an exempt advanced therapy medicinal product meets equivalent standards of quality and safety to those laid down in [F1the Blood Quality and Safety Regulations 2005].U.K.
Textual Amendments
F1Words in Sch. 6 para. 5 substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 26(4); 2020 c. 1, Sch. 5 para. 1(1)